Efficacy of Short-Acting .BETA.-Blockers after Cardiac Surgery

Abstract

）for the treatment of arrhythmia was studied in 10 adult patients who underwent cardiovascular surgery. Onoact was continuously infused at a mean rate of 0.018 mg/kg/min initially and followed by 0.01 mg/kg/min. After the initiation of Onoact infusion, supra-ventricular tachycardia was eliminated in 5 out of 6 patients, and ventricular tachycardia disappeared in all 4 patients. The decrease in systemic blood pressure was not significant. Low-dose continuous infusion of Onoact was safe and effective even in patients just after cardiovascular surgery.

Safety and Efficacy of Low‐Dose Continuous Infusion of Landiolol, an Ultra‐Short‐Acting β‐blocker, in Cardiac Surgery

“…[4][5][6][7][8][9][10] Postoperative SVT is common after cardiac surgery, with a reported incidence ranging from 11-40% after coronary bypass grafting and over 50% after valvular surgery. Previous reports have suggested that af is associated with an increased incidence of congestive heart failure, renal insufficiency, and stroke, all of which prolong hospitalization and increase the rate of rehospitalization after discharge.…”

“…[3][4][5][6][7][8][9][10] In these studies, the dose of landiolol has ranged from 4.7 to 40 mg/kg/min under different clinical situations. [3][4][5][6][7][8][9][10] However, we have found that landiolol is effective for postoperative SVT at doses ranging from 2 to 5 mg/kg/min. Therefore, landiolol can be effective at doses lower than that recommended in the standard guidelines.…”

“…Premature termination of landiolol was not necessary in any of the patients, and many studies have also supported the safety of landiolol, which has a higher 1-selectvity than other -blockers that are currently available. [4][5][6][7][8][9][10] The occurrence of postoperative SVT was lower in the landiolol group compared with the control group, but the difference was not statistically significant. However, postoperative SVT during the continuous infusion of landiolol was suppressed significantly.…”

“…[1][2][3] The efficacy of landiolol for intraoperative and postoperative supraventricular tachyarrythmia (SVT) has been demonstrated in cardiac surgery and in other procedures. [4][5][6][7][8][9][10] However, the dose of landiolol has differed among these studies and has not been clearly determined. Postoperative SVT occurs in 11-40% of patients in coronary artery bypass grafting and in over 50% of patients after valvular surgery, and can lead to hemodynamic deterioration or thromboembolic complications.…”